Jefferies Keeps Their Hold Rating on Masimo (MASI)
Masimo Analyst Ratings
Stifel Maintains Masimo(MASI.US) With Buy Rating, Raises Target Price to $190
Stifel Nicolaus Remains a Buy on Masimo (MASI)
Raymond James Upgrades Masimo to Outperform, Announces $170 Price Target
Wells Fargo Maintains Masimo(MASI.US) With Buy Rating, Maintains Target Price $171
Piper Sandler Maintains Masimo(MASI.US) With Buy Rating, Raises Target Price to $180
Stifel Maintains Masimo(MASI.US) With Buy Rating, Maintains Target Price $170
Masimo Is Maintained at Overweight by Piper Sandler
A Quick Look at Today's Ratings for Masimo(MASI.US), With a Forecast Between $170 to $180
Masimo (MASI) Gets a Hold From Needham
Masimo Analyst Ratings
BTIG Sticks to Their Buy Rating for Masimo (MASI)
Piper Sandler Maintains Masimo(MASI.US) With Buy Rating, Maintains Target Price $165
Piper Sandler Maintains Masimo(MASI.US) With Buy Rating, Maintains Target Price $165
Masimo Is Maintained at Buy by BTIG
Masimo Analyst Ratings
BTIG Maintains Masimo(MASI.US) With Buy Rating, Raises Target Price to $170
C.L. King Initiates Masimo(MASI.US) With Hold Rating
Analysts Have Conflicting Sentiments on These Healthcare Companies: Masimo (MASI), Baxter International (BAX) and Merck & Company (MRK)